Now let’s look at the healthcare stocks also drawing the best long-term targets from experts.\u00a0<\/p>\n
It’s important to remember these targets are not guaranteed to be met, however they can help act as a guide of which stocks may have fallen past fair value<\/a>.<\/p>\n Image source: Getty Images<\/p>\n Pro Medicus Ltd (ASX: PME<\/a>) <\/p>\n Pro Medicus has been one of the most consistently covered healthcare stocks recently as it has continued to fall despite positive outlooks.\u00a0<\/p>\n The company is a provider of medical imaging technology globally.<\/p>\n At the time of writing, Pro Medicus shares are 45% year to date.\u00a0<\/p>\n This is despite the continued flow of new contract wins<\/a> as the drivers of interest in its product remain firmly in place.<\/p>\n It closed yesterday at $120.79 per share.\u00a0<\/p>\n However, brokers see plenty of room<\/a> for a rebound.\u00a0<\/p>\n Recently, Bell Potter placed a buy rating and $240.00 price target, suggesting almost 100% upside over the next 12 months.<\/p>\n Meanwhile, Morgans is even more bullish, with a buy rating and a $275.00 price target.<\/p>\n It’s a similar story for Cochlear.\u00a0<\/p>\n The company is the world’s leading cochlear implant device manufacturer with around half of global market share.<\/p>\n Its share price is currently down 36% year to date, closing yesterday at $165.63 each.\u00a0<\/p>\n However, brokers are confident a recovery is coming.\u00a0<\/p>\n![\"A](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/03\/health-1200x675.jpg\")
<\/p>\n